Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Frustration Drives Japan To Allow Generics Before Side Patents Expire

This article was originally published in PharmAsia News

Executive Summary

TOKYO - In a continuing effort to raise generic drug use, Japan's Ministry of Health, Labor and Welfare has decided to allow generic drugs to be manufactured even before brand drugs' side patents expire, the ministry's Insurance Bureau officials said

You may also be interested in...



Wide Data Gap On Generics Use In Japan Puts Damper On MHLW 30% Generic Target

TOKYO - A wide data gap on generics penetration between studies commissioned by Chuikyo and the Ministry of Health, Labor and Welfare has surfaced, casting clouds over the Japanese government's official target to raise generics use to 30 percent by 2012

Battling Negative Image Of Generics In Japan (Part 2 of 2)

[Editor's note: This is part two of a two-part feature on obstacles in promoting generics in Japan. Part one, which explored negative connotations associated with with the term "generic," appeared in PharmAsia News, March 19, 2009.]

Japanese Pharmas Agree To Lower NHI Prices When Generic Uptake Is Slow

TOKYO - Manufacturers would take "certain degrees of action" to lower national health insurance listed prices if generic penetration failed to reach a certain level in the same composite group during a drug's patented period, according to an industry proposal during the latest Chuikyo pharmaceutical price expert subcommittee meeting March 18

UsernamePublicRestriction

Register

PS140995

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel